Abstract
Methods: The synthesis of conjugates of flutamide with resorcinarene-PAMAM-dendrimers as well as alkyl and ethyl phenyl chains in the lower part of the macrocycle as a nucleus and diethylenetriamines in the dendritic branches gives the opportunity to obtain conjugates in one step of synthesis with 16 and 64 flutamide moieties in the structure.
Results: The in vitro anticancer studies showed that the conjugates of flutamide are more active than the free flutamide and the flutamide derivatives, thus diminishing the amount of flutamide used. The resorcinarenedendrimer- flutamide conjugates with a high drug payload improve the activity of the drug.
Conclusion: This is important in delivering a sufficient amount of flutamide and suggests that the dendrimer facilitates more of the drug being introduced into cells. It was also observed that the new conjugates are less toxic than the anti-androgens.
Keywords: Dendrimers, conjugates, flutamide, anticancer, apoptosis, anti-androgens.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Anticancer Activity of Resorcinarene-PAMAM-Dendrimer Conjugates of Flutamide
Volume: 18 Issue: 7
Author(s): Luis D. Pedro-Hernández, Elena Martínez-Klimova*, Mark E. Martínez-Klimov, Sandra Cortez-Maya, Ana C. Vargas-Medina, Teresa Ramírez-Ápan, Simón Hernández-Ortega and Marcos Martínez-García
Affiliation:
- Instituto de Fisiologia Celular, Universidad Nacional Autonoma de Mexico, Ciudad Universitaria, Circuito Exterior, Coyoacan, C.P. 04510, Mexico D.F,Mexico
Keywords: Dendrimers, conjugates, flutamide, anticancer, apoptosis, anti-androgens.
Abstract: Methods: The synthesis of conjugates of flutamide with resorcinarene-PAMAM-dendrimers as well as alkyl and ethyl phenyl chains in the lower part of the macrocycle as a nucleus and diethylenetriamines in the dendritic branches gives the opportunity to obtain conjugates in one step of synthesis with 16 and 64 flutamide moieties in the structure.
Results: The in vitro anticancer studies showed that the conjugates of flutamide are more active than the free flutamide and the flutamide derivatives, thus diminishing the amount of flutamide used. The resorcinarenedendrimer- flutamide conjugates with a high drug payload improve the activity of the drug.
Conclusion: This is important in delivering a sufficient amount of flutamide and suggests that the dendrimer facilitates more of the drug being introduced into cells. It was also observed that the new conjugates are less toxic than the anti-androgens.
Export Options
About this article
Cite this article as:
Pedro-Hernández D. Luis , Martínez-Klimova Elena *, Martínez-Klimov E. Mark , Cortez-Maya Sandra , Vargas-Medina C. Ana , Ramírez-Ápan Teresa , Hernández-Ortega Simón and Martínez-García Marcos , Anticancer Activity of Resorcinarene-PAMAM-Dendrimer Conjugates of Flutamide, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (7) . https://dx.doi.org/10.2174/1871520618666171219114532
DOI https://dx.doi.org/10.2174/1871520618666171219114532 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery “SLY AS A FOXO”: New Paths with Forkhead Signaling in the Brain
Current Neurovascular Research Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species
Protein & Peptide Letters The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry The Emerging Roles of Extracellular Vesicles in Ovarian Cancer
Current Drug Metabolism Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Biotransformation of Silybin and its Congeners
Current Drug Metabolism Properties and Recent Advantages of N,N’-dialkylimidazolium-ion Liquids Application in Electrochemistry
Current Analytical Chemistry Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Developmental Expression of the Translocator Protein 18 kDa (TSPO) in Testicular Germ Cells
Current Molecular Medicine Biological Evaluation of 3-Acyl-2-Arylamino-1,4-Naphthoquinones as Inhibitors of Hsp90 Chaperoning Function
Current Topics in Medicinal Chemistry CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer
Current Pharmaceutical Design